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Abstract
Introduction: Invasive pulmonary aspergillosis is a leading cause of mortality and morbidity in
bone marrow transplant recipients. Establishing the diagnosis remains a challenge for clinicians
working in acute care setting. However, prompt diagnosis and treatment can lead to favourable
outcomes
Case presentation: We report a case of invasive aspergillosis occurring in a 39-year-old
Caucasian female 10 years after an allogeneic haematopoietic bone marrow transplant, and 5 years
after stopping all immunosuppression. Possible risk factors include bronchiolitis obliterans and
exposure to building dust (for example, handling her husband's dusty overalls). There are no similar
case reports in the literature at this time.
Conclusion: High clinical suspicion, especially in the setting of failure to respond to broad-
spectrum antibiotics, should alert clinicians to the possibility of invasive pulmonary aspergillosis,
which, in this case, responded to antifungal therapy.
Introduction
Clear cut risk factors for developing invasive pulmonary
aspergillosis (IPA) include neutropenia, immunosuppres-
sive therapy, cytomegalovirus infection and chronic graft
versus host disease. IPA in patients after allogeneic hae-
matopoietic stem cell transplant (HSCT) is associated
with a poor prognosis and diagnosis is often delayed.
Mortality rates have been reported to be in the region of
87 to 90% [1-4].
Pulmonary complications of post-HSCT are generally
divided into two groups: early (<100 days) and late (>100
days) complications. The "high-risk" period is described
as being 6 to12 months after bone marrow transplant
(BMT) with resolution of immune impairment 12 to15
months post-allogeneic HSCT [5].
Median time to diagnosis is generally thought to be in the
region of 60 to100 days after allogeneic transplantation.
Although cases are described infrequently in the literature
of IPA beyond 100 days, rarely has the time exceeded 210
days. One case occurring 470 days after HSCT of Aspergil-
lus ustus infection has been reported [6]. However, presen-
tation 10 years post-HSCT and 5 years post cessation of
immunosuppression is exceptionally rare. Numerous pro-
spective and retrospective studies of pulmonary complica-
tions following HSCT do not include a similar case.
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Case presentation
We report the case of a 25-year-old Caucasian lady who
underwent a matched related donor stem cell transplant
in June 1994 for underlying chronic myeloid leukaemia in
the first chronic phase. She was conditioned with cyclo-
phosphamide total body irradiation and received recom-
binant DNA- monoclonal antibody (Cam-Path1H). She
received fungal prophylaxis with fluconazole at a dosage
of 100 mg per day for 6 months post transplant. In Janu-
ary 1996 she experienced cytogenetic relapse with Phila-
delphia positivity and subsequently received four doses of
donor lymphocyte infusions. In mid-1997, she started to
complain of poor exercise tolerance and lung function
tests revealed FEV1 1.05 litres (predicted 3.28, % predicted
= 32) VC 2.2, (predicted 3.78, % predicted = 58) RV 2.4
and DLCO 5.8 (predicted 8.1, % predicted 72) interpreted
as moderate airflow obstruction according to GOLD crite-
ria. An open lung biopsy revealed evidence of obliterative
bronchiolitis thought to be a consequence of the donor
lymphocyte infusions received previously. Treatment with
cyclosporin and corticosteroids was commenced. Her
lung function improved (DLCO improved to 6.2); how-
ever, she developed marked steroid-induced myopathy.
In April 1998, her condition deteriorated with frequent
chest infections and worsening lung function (DLCO
5.76). This required a further increase in her steroid dose.
In July 1998 she required intravenous immunoglobulin
infusions for hypogammaglobulinaemia. The frequency
of chest infections decreased gradually in response to this
with a concomitant symptomatic improvement in her
lung function and exercise tolerance. By autumn 1999 her
steroid therapy was being tapered off.
Unfortunately, she did not enjoy good health for long; in
2001 she suffered recurrent bouts of bronchitis and occa-
sional pneumonia. Her lung function tests were consist-
ent with airflow obstruction caused by bronchiolitis
obliterans thought to be a sequel to graft versus host dis-
ease (GVHD).
A computed tomography (CT) scan of her thorax in May
2001 confirmed changes consistent with the above and
also a number of pulmonary nodules in the left upper
lobe and evidence of bronchiectasis. At this point her
immunoglobulin levels were noted to be within normal
limits and she did not require replacement. Immunosup-
pressant therapy was discontinued in 1999–2000.
In September 2005 at the age of 39, she was admitted to
our hospital with shortness of breath, wheeze, pyrexia,
cough productive of yellow sputum and pleuritic chest
pain. Her arterial oxygen saturations were 95% on room
air. Her chest radiograph showed right mid-zone and
basal opacification and loss of costophrenic angle.
Although her total white blood cell count was normal, her
C-reactive protein was raised at 269 (normal <10 mg).
Fever continued despite broad-spectrum antibiotic ther-
apy with intravenous third generation cephalosporin, pip-
eracillin and macrolide therapy.
Her CD4 count was normal with a normal lymphocyte
profile. No antibodies were detected to common causes of
atypical and viral pneumonia. Absolute neutrophil count
(ANC) and white blood cell (WBC) on admission were
18,280 mm3  and 25,400 mm3  respectively with lym-
phocyte count of 3160 mm3. CD4 cell count was also
within normal limits. Immunoglobulin levels revealed a
high globulin level 45 g/L, IgG 20.1 g/L, IgM 4.4 g/L all
within normal limits.
Sputum cultures grew Aspergillus fumigatus in three sam-
ples which was fully susceptible to itraconazole, voricona-
zole and amphotericin B.
CT scan of the thorax showed multifocal air space shad-
owing with at least 20 areas of disease and right upper
lobe consolidation. In addition, classical findings of halo
sign and signet ring sign were reported (Figures 1 and 2),
in conjunction with strongly positive serology results
(Table 1). Her initial results included negative serum
galactomannan and negative blood Aspergillus PCR test
but strongly positive precipitins to A. fumigatus at a dilu-
tion level of 1/256.
September 2005(CT Thorax): Halo sign Figure 1
September 2005(CT Thorax): Halo sign. Note the so-
called "halo sign", seen as a blush around the lesion. This sign 
is indicative of haemorrhage and highly suggestive of infection 
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The diagnosis of invasive aspergillosis was made. She was
treated with intravenous voriconazole only.
Follow-up CT scans in Oct 2005 (Figure 3) and more
recently February 2006 showed marked improvement in
the original areas of invasive aspergillosis and some resid-
ual ground-glass shadowing. She continues on oral vori-
conazole therapy and has made remarkable clinical
progress. This is also reflected in her immunological and
radiological markers (Table 1).
Subsequent to her discharge, her husband raised the pos-
sibility of major exposure to dust following her handling
his overalls prior to her illness. He had been involved in
partial house demolition and his clothes were extremely
dusty. She received 9 months of voriconazole with a
trough concentration of 1,900 ng/mL and post-dose con-
centrations varying from 2,030 to 3,860 ng/mL. Her
Aspergillus precipitin titre fell gradually to 1/2 at the end of
therapy, and was unchanged a year after discontinuation
of therapy.
Discussion
Pulmonary infection or chronic graft versus host disease
leading to bronchiolitis obliterans as in our case could
predispose to IPA. It is certainly recognised as a late non-
infectious complication known to occur in 2 to 10 % of
bone marrow transplant recipients which occurs almost
exclusively in allogeneic BMT or stem cell recipients. IPA
10 years post HSCT is exceptionally rare regardless of aeti-
ology.
Signs and symptoms may be confused with routine chest
infections and include: dyspnoea, initially on exertion
and later at rest, cough, wheeze and fever. Chest X-ray
findings include hyperinflation. High-resolution CT of
thorax is more informative. Typical features include focal
or diffuse areas of decreased parenchymal attenuation
(mosaic attenuation), bronchial wall thickening and air
trapping.
Pulmonary function tests show obstructive patterns with
low FEV1 and low FEV1/FVC ratio. In addition low diffu-
sion capacity is noted. Most clinicians base the diagnosis
on the aforementioned CT and pulmonary function find-
ings in the setting of allogeneic BMT. Again, survival rates
are not favourable in this cohort of patients.
Major exposure to Aspergillus spores may contribute to the
risk. Contaminated air-ventilation systems have been
implicated in clusters of infection within departments [7].
September 2005 (CT Thorax): Multifocal areas of infection Figure 2
September 2005 (CT Thorax): Multifocal areas of 
infection.
Table 1: Aspergillus precipitins test results over time.
Date Aspf 2109 Aspf 2140 Dilution
Sep 2005 detected detected 1/256
Dec 2005 detected detected 1/64
October 2005 (CT Thorax): Resolution of areas of consoli- dation and "signet ring sign" Figure 3
October 2005 (CT Thorax): Resolution of areas of 
consolidation and "signet ring sign". The signet ring sign 
is a finding seen on CT scans of the thorax. It consists of a 
small circle of soft tissue attenuation that abuts a ring of soft 
tissue attenuation surrounding a larger low attenuating circle 
of air and is indicative of bronchiectasis.Journal of Medical Case Reports 2009, 3:26 http://www.jmedicalcasereports.com/content/3/1/26
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Hospital water could be a major source of filamentous
fungi, in particular Aspergillus fumigatus [8-10]. We have
recently noted 'primary' A. fumigatus infection after expo-
sure to bark chippings presumably heavily contaminated
with fungus in normal people [11].
The diagnosis of IPA always remains a challenge in immu-
nocompromised patients, often only made post-mortem.
In our case we feel the diagnosis of IPA is merited as
defined by the recently published European Organization
for Research and Treatment of Cancer/Mycoses Study
Group (EORTC-MSG) criteria. The revised guidelines sug-
gest that a diagnosis of probable invasive fungal disease
can be made on the basis of host factors, clinical features
and mycology [12].
In this case our patient had received allogeneic HSCT, had
chronic GVHD, and had had prior treatment with T-cell
immunosuppressant drugs (Cam-Path 1H). However, she
was not deemed to be immunocompromised at the time
of diagnosis. She did present with a pyrexial illness unre-
sponsive to broad spectrum antibiotic therapy. As regards
to clinical features, she had clinical signs and radiological
signs consistent with lower respiratory tract infection. CT
findings confirmed the presence of halo signs and multi-
focal areas of air space shadowing and evidence of bron-
chiolitis obliterans. Mycological samples in the form of
three separate sputum cultures revealed Aspergillus fumiga-
tus which was fully sensitive. In addition the strongly pos-
itive Aspergillus precipitins to A. fumigatus, makes it likely
that this patient had probable invasive aspergillosis on the
basis of EORTC-MSG criteria (despite not being immuno-
compromised) although on clinical grounds there was no
doubt that the diagnosis was one of IPA. Other features
that should alert physicians to the possibility of IPA
include sinus infection, ear pain or discharge, facial pain
or swelling, localised pallor of nasal septum or turbinate
mucosa, and orbital symptoms. Aspergillus  may invade
pulmonary vasculature leading to haemoptysis or pulmo-
nary haemorrhage which may be the presenting com-
plaint.
The role of Aspergillus precipitins and polymerase chain
reaction (PCR) in the diagnosis of IPA remains undefined.
Conclusion
Radiological, serological and respiratory samples helped
in making the diagnosis of IPA in this case and were
instrumental in the commencement of appropriate anti-
fungal therapy. Often treatment has to be started on the
basis of clinical suspicion in order to prevent poor out-
come. Our case highlights that even after 10 years post
HSCT, the diagnosis of IPA should be considered and is
treatable.
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